It is on the labels, the day-after timing is not a coincidence, and the thing most likely to be missed is not the drug at all.
If you are wiped out the day after your shot and fine by Thursday, that pattern is real and this page explains where it comes from.
Fatigue hit 11% of people on Wegovy against 5% on placebo. On Zepbound it ran 5%, 6% and 7% across the three doses against 3%.12 So the drug adds about six points for semaglutide and four for tirzepatide. That is real, and a long way from the universal experience it can look like online. If you are on Ozempic or Mounjaro, your own label does not give you this figure, and the section below sets out why.
The day-after timing lines up with the drug levels. Semaglutide peaks 1 to 3 days after the shot. Tirzepatide peaks 8 to 72 hours after.13 Both windows cover the next day. Nobody has checked whether tiredness tracks those curves, so this is timing that fits and not a proven cause. The people who describe the pattern are not imagining it.
The harder part is that fatigue has at least four candidate causes here and only some of them are the drug. The one that gets missed is iron, and it is the only one on the list a blood test settles.
How common is fatigue on a GLP-1?
Between 5% and 11% depending on the drug and dose, and lower than the discussion around it suggests.
| Product | Molecule and indication | Fatigue on the drug | On placebo |
|---|---|---|---|
| Wegovy 2.4 mg | Semaglutide, weight | 11% (Table 3), 9% (Table 4) | 5% |
| Wegovy 7.2 mg | Semaglutide, weight | 11% | 5% |
| Zepbound 5 mg | Tirzepatide, weight | 5% | 3% |
| Zepbound 10 mg | Tirzepatide, weight | 6% | 3% |
| Zepbound 15 mg | Tirzepatide, weight | 7% | 3% |
| Ozempic | Semaglutide, diabetes | Listed with no percentage | Not given |
| Mounjaro | Tirzepatide, diabetes | Not in the tables | Not given |
From the four labels, all read at source. The Wegovy figures are from section 6.1, with Table 3 covering the 2.4 mg trials at 2,116 on drug against 1,261 on placebo, and Table 4 covering the 7.2 mg trials, where the 2.4 mg arm is reported at 9% instead of 11%.1 The Zepbound figures are from section 6.1, Table 1, pooling its two weight-management trials, with 958 participants on placebo and 630, 948 and 941 on the three doses.2
If you are on Ozempic or Mounjaro, your label will not give you this number. The gap matters before you go looking. Ozempic lists fatigue only among "other adverse reactions with a frequency of >0.4%", with no percentage attached.4 Mounjaro does not list fatigue in its adverse reaction tables at all. Those carry nausea, diarrhoea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain.3
Those are the same two molecules. Semaglutide is Wegovy for weight and Ozempic for diabetes; tirzepatide is Zepbound for weight and Mounjaro for diabetes. The rates above were measured in the weight-management trials, and the diabetes labels for the identical drugs either give the symptom without a figure or omit it. So a reader on Ozempic who checks their own label and finds nothing useful has not missed anything. The number was never put there.
The table changes how you read the rest, in three ways.
- The placebo rate is not zero. Between 3% and 5% of people reported fatigue without any drug in them. Fatigue is common in the general population and some of what people attribute to a GLP-1 would have happened anyway.
- The excess is smaller than it feels. Semaglutide adds about six points over placebo, roughly one extra person in seventeen. Tirzepatide at its top dose adds four, roughly one in twenty-five.
- It tracks dose in both molecules. Tirzepatide rises 5, 6 and 7% across 5, 10 and 15 mg. Semaglutide rises 9% to 11% between its two weight doses in the same set of trials.12 A dose relationship in both is the clearest signal in the data.
For retatrutide there is no trial figure, and the numbers circulating online do not agree with each other. The phase 2 paper reports adverse events occurring in at least 5% of participants, and fatigue is not among the events it lists.5 Pages quoting a retatrutide fatigue rate give 8 to 10%, 6 to 10% against 4%, and 10 to 12% against 4%, all attributed to the same paper. At least one of them also describes the 338-person phase 2 trial as TRIUMPH-1. That is a different and much larger study. Treat all of those figures as unsourced.
What does exist is a study of what people report. Researchers classified 148,640 retatrutide posts and comments, identified 45,592 from 13,589 users describing current use, and mapped the symptoms they attributed to it. Of those users, 7,823 had at least one mapped symptom after exclusions. Fatigue was among the most frequently reported, alongside appetite increase, increased energy, nausea, food craving, insomnia and heart rate terms.6
The authors make the point that matters here: this profile diverges from the phase 2 trial, where gastrointestinal events dominated. People buying retatrutide outside a trial report a different pattern from the one the trial recorded, and fatigue is near the top of it. That is not a rate and it cannot be compared with the label figures above, but it is the best evidence that exists for a compound nobody has approved.
Why am I exhausted the day after my shot?
The mechanical explanation for this one is real, and the labels supply it.
Semaglutide's maximum concentration is reached 1 to 3 days post dose.1 Tirzepatide's is reached 8 to 72 hours post dose.3 Those are the labels' own figures, in their pharmacokinetics sections.
So someone injecting on a Sunday is at peak drug level somewhere between Monday and Wednesday. That is exactly the window people describe.
What that does and does not establish. It establishes that the timing people report coincides with peak concentration instead of contradicting it. That is more than can be said for most forum theories. It does not establish that the drug concentration causes the tiredness, because no trial measured fatigue against the concentration curve. The two have never been plotted against each other.
So the pattern fits, the mechanism is unproven, and anyone telling you it is definitely the peak or definitely not is going beyond the evidence.
What else could be causing it?
At least four things can produce it, and they are known to very different degrees. Most discussion treats them as interchangeable.
- You are eating far less. This is the explanation most pages give and the best supported one. These drugs work by making you eat less, and a sustained energy deficit makes anyone tired. It is also the one that does not fit a sharp dip the day after a shot when the rest of your week is fine. If your tiredness has a shape, this explanation does not have one.
- You are drinking less without noticing. Eating much less means drinking much less, since food carries a substantial share of your daily water. Both labels carry warnings about volume depletion and kidney injury, and dehydration makes you tired long before it does anything that gets a name. Our dehydration guide follows that path properly.
- Low blood sugar, but probably not yours. Both labels address hypoglycaemia and both scope it the same way: the risk is raised in people also taking insulin or a sulfonylurea.12 On a GLP-1 alone, with no other diabetes medication, this is the least likely of the four, and it is the first thing replies online reach for.
- You might be short of something, and nobody checked. Eating substantially less of everything for months is a plausible route to being low in iron, B12, folate or vitamin D. None of these labels reports nutrient status, and no trial we found tracked it. The one that gets missed is this, and a blood test settles it.
The pattern to watch for is a drug that is a plausible cause absorbing the blame while a treatable cause sits underneath, unexamined. Iron deficiency is the clearest candidate, because it produces exactly this kind of tiredness, it is common, and it is cheap to rule out. Our bloodwork guide covers which tests to run and why a result without a baseline is weak information.
How long does GLP-1 fatigue last?
Nobody has published an answer. For tirzepatide the dose relationship is the only measured clue, and it points one way.
Fatigue rose with dose in the Zepbound trials, 5% to 6% to 7%.2 That is a dose effect, not a time effect, and it suggests escalating while you already feel wrung out makes things more likely to worsen.
Beyond that, neither label reports how fatigue changed over the course of the trial. The claim that it settles after a few weeks is widely repeated and we could not source it to either label or to a trial publication.
What is documented is adjacent but not the same thing. Lilly reports that most adults who stopped Zepbound because of adverse reactions did so in the first few months, and because of gastrointestinal effects.2 That tells you when people leave and why, not whether the tiredness of those who stay improves.
What can be said: the gut effects on these drugs cluster around dose increases and fade at a steady dose, a pattern that is well documented. If your tiredness is downstream of nausea and eating almost nothing for four days, it would be expected to follow the same shape. If it is downstream of low iron, it will not.
Could it be your sleep rather than the drug?
Quite possibly, and it cuts both ways. Sleep is missing from most coverage of this.
The drug can disturb your sleep. Nausea, reflux and needing to get up in the night are all more likely in the early weeks and after each dose increase, and broken sleep produces exactly the tiredness people then attribute to the drug directly. The chain of causation there is real, and the first link is a gut effect, not fatigue.
The drug is also approved to treat a cause of daytime tiredness. Zepbound carries an indication for moderate to severe obstructive sleep apnoea in adults with obesity, to improve their sleep apnoea.2 Untreated sleep apnoea is one of the commonest reasons for feeling exhausted during the day, and for some people on tirzepatide the drug is treating it.
So on the same drug, in the same week, one mechanism can make you more tired and another less. That is part of why individual accounts contradict each other so thoroughly, and a reason to treat any single account with caution, including this one.
If you snore, wake unrefreshed, or someone has told you that you stop breathing at night, that is a different investigation from anything on this page and a more productive one.
Should you move your injection day?
People report doing it and nobody has studied it.
A common suggestion is to shift the injection to a Thursday or Friday so the heaviest days land on a weekend. The reasoning follows the peak concentration window above, and it is coherent.
What exists: the labels allow the day of weekly dosing to be changed if necessary, with a minimum gap between doses. What does not exist: any trial measuring whether fatigue tracks the day of the week relative to the injection, or whether moving the day helps anyone.
So this is a widely used practice with a plausible rationale and no evidence either way. If you are going to do it, the spacing rules are a prescriber question, and our guide on missed doses covers what each label says about changing the day.
When should you get this looked at?
Tiredness and brain fog are the symptoms most easily explained away. That is how a treatable cause goes unexamined for months.
Breathlessness on exertion that is new, or a racing heart at rest. Both can accompany anaemia.
Tiredness that keeps worsening rather than fluctuating, or that does not improve at all after a week at a steady dose.
Dizziness on standing, passing very little urine, or a dry mouth you cannot shift. Those point at fluid loss instead of fatigue.
Shakiness, sweating, confusion or a pounding heart that eases after eating, especially if you also take insulin or a sulfonylurea.
Fatigue with any fever, with unexplained bruising, or alongside a change in your stools or your cycle, all of which have causes unrelated to any of this.
The general one: exhaustion that is stopping you doing ordinary things needs a blood test rather than another month of assuming.
Common questions
Does Ozempic or Mounjaro make you tired?
Fatigue appears in the labels for the weight-management versions of both molecules: 11% on Wegovy, the semaglutide product, against 5% on placebo, and 5 to 7% on Zepbound, the tirzepatide product, against 3%. Ozempic and Mounjaro are the same molecules at doses used for type 2 diabetes.
How long does GLP-1 fatigue last?
Neither label reports how it changed over the trial, and the widely repeated claim that it settles after a few weeks is one we could not source. What is documented is that it rises with dose for tirzepatide.
How common is fatigue on GLP-1 drugs?
Fatigue was reported by 11% of people on Wegovy against 5% on placebo, and by 5% to 7% on Zepbound depending on dose against 3% on placebo. The placebo figures matter: fatigue is common without any drug.
Why am I exhausted the day after my shot?
The timing fits the drug levels. Semaglutide reaches maximum concentration 1 to 3 days post dose and tirzepatide 8 to 72 hours post dose, both from the labels. No trial has measured fatigue against the concentration curve, so the pattern fits without being proven.
Is it low blood sugar?
Only likely if you also take insulin or a sulfonylurea. That is how both labels scope the hypoglycaemia risk. For someone on a GLP-1 alone without diabetes medication, it is the least likely of the four explanations and the one most often blamed.
Could it be something other than the drug?
Yes, and iron, B12, folate and vitamin D are the common ones after months of eating much less. None of the trials tracked nutrient status. The cause most often missed is iron, and it is the only one on the list a blood test settles.
Does retatrutide cause fatigue?
No trial rate exists. The phase 2 paper lists adverse events occurring in at least 5% of participants and fatigue is not among them, and the percentages circulating online contradict each other. What does exist is a study of 13,589 people reporting current use on Reddit, 7,823 of whom had at least one mapped symptom, and fatigue was among the most frequently reported, a pattern the authors note diverges from the trial profile.
Could it be my sleep rather than the drug?
Possibly, and in two directions. Nausea and reflux in the early weeks break sleep, and broken sleep produces the tiredness people then blame on the drug directly. Separately, Zepbound is approved to treat moderate to severe obstructive sleep apnoea in adults with obesity, itself a common cause of daytime exhaustion.
Should I move my injection day?
People report shifting it so the heaviest days land on a weekend, and the reasoning follows the peak concentration window. No trial has measured whether fatigue tracks the day relative to the injection or whether moving it helps. The labels allow the day to be changed within a minimum spacing. The spacing itself is a prescriber question.
Why does my Ozempic label not mention fatigue?
Because the figures were measured in the weight-management trials, not the diabetes ones. Ozempic lists fatigue only among other adverse reactions with a frequency above 0.4% and gives no percentage. Mounjaro does not list it in its adverse reaction tables at all. Wegovy and Zepbound are the same two molecules at weight-management doses, and both report it with numbers. If you are on the diabetes brand and your label is silent, the rates from the weight labels are the closest thing available.
Is there a higher Wegovy dose now?
Yes. The label covers a 7.2 mg dose alongside 2.4 mg, and the trials behind it report fatigue at 11% on 7.2 mg, 9% on 2.4 mg and 5% on placebo. The 2.4 mg figure appears as 11% in the earlier set of trials and 9% in this one, so the range for 2.4 mg is 9 to 11%.
Does the dose matter?
For tirzepatide, yes: 5%, 6% and 7% at 5, 10 and 15 mg. The dose relationship is the clearest signal in either label, and it is the argument for holding a dose instead of climbing while you feel wrung out.
When should I see a doctor about it?
Breathlessness on exertion, a racing heart at rest, tiredness that keeps worsening, dizziness on standing, passing very little urine, or shakiness that eases after eating. Also any fatigue severe enough to stop you doing ordinary things.
Sources
- Wegovy (semaglutide injection) prescribing information, revised 06/2026. Novo Nordisk. novo-pi.com/wegovy.pdf. Read at source. Section 12.3: "Maximum concentration of semaglutide is reached 1 to 3 days post dose." Section 6.1, Table 3, covering the 2.4 mg trials: fatigue in 11% on Wegovy 2.4 mg once weekly against 5% on placebo, with 2,116 participants on drug and 1,261 on placebo. Section 6.1, Table 4, covering the 7.2 mg trials: fatigue at 5% on placebo, 9% on 2.4 mg and 11% on 7.2 mg. The 2.4 mg figure therefore appears as 11% in one table and 9% in the other, measured in different trial sets, and both are reported here rather than one being chosen. Hypoglycaemia risk is scoped to concomitant insulin or insulin secretagogues.
- Zepbound (tirzepatide) prescribing information, Adverse Reactions. pi.lilly.com. The approved label. Fatigue reported in 5%, 6% and 7% of patients at 5, 10 and 15 mg against 3% on placebo in the pooled weight-management trials. The label addresses hypoglycaemia risk with concomitant insulin or insulin secretagogues, carries warnings on volume depletion and acute kidney injury, and carries an indication for moderate to severe obstructive sleep apnoea in adults with obesity, to improve their obstructive sleep apnoea. Figures from section 6.1, Table 1, pooled across the two trials, with 958 placebo participants and 630, 948 and 941 assigned to 5, 10 and 15 mg.
- Mounjaro (tirzepatide injection) prescribing information, revised 01/2026. Eli Lilly, via FDA Drugs@FDA. accessdata.fda.gov. Read at source. Section 12.3: "Following subcutaneous administration, the time to maximum plasma concentration of tirzepatide ranges from 8 to 72 hours", with "an elimination half-life of approximately 5 days". Fatigue does not appear in the adverse reaction tables in section 6.1, which list nausea, diarrhoea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain.
- Ozempic (semaglutide injection) prescribing information, revised 5/2026. Novo Nordisk, via DailyMed. dailymed.nlm.nih.gov. Read at source. Section 12.3: "Maximum concentration of semaglutide is reached 1 to 3 days post dose", the same figure as the Wegovy label. Section 6.1 Table 1, reactions in at least 5% of Ozempic-treated patients, lists nausea, vomiting, diarrhoea, abdominal pain and constipation with percentages. Fatigue appears separately under other adverse reactions with a frequency of greater than 0.4%, grouped with dysgeusia and dizziness, and no percentage is given for it.
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine 2023;389:514-526. doi:10.1056/NEJMoa2301972. Phase 2 trial, 338 adults, 48 weeks. Table 3 reports adverse events during treatment occurring in at least 5% of total participants; the events named are gastrointestinal, and fatigue is not among them. Adverse events overall were reported in 70% of the placebo group and 73 to 94% of the retatrutide groups. Discontinuation for adverse events occurred in 6 to 16% of retatrutide participants and none on placebo.
- Self-Reported Side Effects Among Reddit Users Taking Nonapproved Retatrutide. Preprint, medRxiv, version 2 posted August 18, 2026. doi:10.64898/2026.05.28.26352819. Not peer reviewed. Version 2 is noted on the record as revised for clarity, with no new data or analyses, so the version 1 figures stand. A validated large language model classified self-reported retatrutide use and extracted author-attributed symptoms mapped to MedDRA preferred terms, from 148,640 retatrutide-related posts and comments, identifying 45,592 from 13,589 unique users reporting current use between March 2023 and December 2025, of whom 7,823 had at least one mapped symptom after exclusions. The authors report that, unlike the phase 2 trial findings dominated by gastrointestinal events, posts most often described appetite increase, fatigue, increased energy, nausea, food craving, insomnia and elevated heart rate. The authors note that Reddit users may not represent all users and that those with adverse events may be more likely to post.
Citing this page. Peptide Decoding. GLP-1 Fatigue: Why You Are Exhausted the Day After Your Dose. Label figures as cited. https://peptidedecoding.com/guides/glp1-fatigue